Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
13 mai 2024 16h05 HE
|
Generation Bio Co.
- Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP) - ASGCT poster presentations described...
Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
09 mai 2024 06h59 HE
|
Generation Bio Co.
Data presented show immune-quiet DNA (iqDNA) is a partially single-stranded DNA cargo that maintains expression while evading innate immune sensorsRapid enzymatic synthesis continues to improve iqDNA...
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
22 avr. 2024 17h31 HE
|
Generation Bio Co.
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today...
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
02 avr. 2024 06h59 HE
|
Generation Bio Co.
CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
06 mars 2024 16h20 HE
|
Generation Bio Co.
- Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia - Development of breakthrough...
Generation Bio to Present at the 2024 TD Cowen Health Care Conference
27 févr. 2024 06h59 HE
|
Generation Bio Co.
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 16h05 HE
|
Generation Bio Co.
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
29 nov. 2023 06h59 HE
|
Generation Bio Co.
Company to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell typesDevelopment of immune-quiet DNA (iqDNA)...
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results
09 nov. 2023 16h15 HE
|
Generation Bio Co.
- Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics - Proprietary cell-targeted LNP delivery system...
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform
26 oct. 2023 06h59 HE
|
Generation Bio Co.
70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle...